Cereno Scientific AB (OSTO:CRNO B) 3-Year Share Buyback Ratio : -38.80% (As of Mar. 2025)

View and export this data going back to 2016. Start your Free Trial

What is Cereno Scientific AB 3-Year Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Cereno Scientific AB's current 3-Year Share Buyback Ratio was -38.80%.

The historical rank and industry rank for Cereno Scientific AB's 3-Year Share Buyback Ratio or its related term are showing as below:

OSTO:CRNO B' s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -93 Med: -50.7 Max: -10
Current: -38.8

During the past 10 years, Cereno Scientific AB's highest 3-Year Share Buyback Ratio was -10.00%. The lowest was -93.00%. And the median was -50.70%.

OSTO:CRNO B's 3-Year Share Buyback Ratio is ranked worse than
89.96% of 677 companies
in the Drug Manufacturers industry
Industry Median: -2.2 vs OSTO:CRNO B: -38.80

Competitive Comparison of Cereno Scientific AB's 3-Year Share Buyback Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Cereno Scientific AB's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cereno Scientific AB's 3-Year Share Buyback Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cereno Scientific AB's 3-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Cereno Scientific AB's 3-Year Share Buyback Ratio falls into.

Save Embed

;

Save Embed

;

Cereno Scientific AB 3-Year Share Buyback Ratio Calculation

This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Cereno Scientific AB (OSTO:CRNO B) 3-Year Share Buyback Ratio Explanation

A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Cereno Scientific AB 3-Year Share Buyback Ratio Related Terms

Thank you for viewing the detailed overview of Cereno Scientific AB's 3-Year Share Buyback Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Cereno Scientific AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cereno Scientific AB (OSTO:CRNO B) » Definitions » 3-Year Share Buyback Ratio

Comparable Companies

Traded in Other Exchanges

4A1:Germany

Address

BioVentureHub, Pepparedsleden 1, Molndal, SWE, 431 83

Website

https://www.cerenoscientific.se

Cereno Scientific AB is developing a pipeline of preventive therapeutics to treat cardiovascular and rare diseases by epigenetic modulation through histone deacetylase inhibition (HDACi). The company's lead program, CS1, is a phase two dual-acting antithrombotic drug aimed at venous thrombosis and stroke prevention for atrial fibrillation. Cereno Scientificalso evaluates the potential of epigenetic modulation for rare diseases related to pulmonary fibrosis, thrombosis, inflammation, and high blood pressure in the pulmonary circulation system.

Cereno Scientific AB Headlines

No Headlines